The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
CLINICAL SYNTHESISFull Access

Quick Reference Psychosomatic Medicine

Med-Psych Drug-Drug Interactions Update An Overview of Psychotropic Drug-Drug Interactions
Published Online:https://doi.org/10.1176/foc.7.3.foc347

Abstract

Source: Sandson NB, Armstrong SC, Cozza KL: Med-Psych Drug-Drug Interactions Update An Overview of Psychotropic Drug-Drug Interactions. Psychosomatics 2005;46:464–494. Reprinted with permission. Please refer to the full article for specific citations of each interaction.

The psychotropic drug-drug interactions most likely to be relevant to psychiatrists' practices are examined. The metabolism and the enzymatic and P-glycoprotein inhibition/induction profiles of all antidepressants, antipsychotics, and mood stabilizers are described; all clinically meaningful drug-drug interactions between agents in these psychotropic classes, as well as with frequently encountered nonpsychotropic agents, are detailed; and information on the pharmacokinetic/pharmacodynamic results, mechanisms, and clinical consequences of these interactions is presented. Although the range of drug-drug interactions involving psychotropic agents is large, it is a finite and manageable subset of the much larger domain of all possible drug-drug interactions. Sophisticated computer programs will ultimately provide the best means of avoiding drug-drug interactions. Until these programs are developed, the best defense against drug-drug interactions is awareness and focused attention to this issue.

Appendix 1. Significant Drug-Drug Interactions Involving Antidepressants

Appendix 1. Significant Drug-Drug Interactions Involving Antidepressants

Appendix 1.
Appendix 1.
Appendix 1.
Appendix 1.
Appendix 1.
Appendix 1.

Appendix 1. Significant Drug-Drug Interactions Involving Antidepressants

Enlarge table

Appendix 2. Significant Drug-Drug Interactions Involving Antipsychotics

Appendix 2. Significant Drug-Drug Interactions Involving Antipsychotics

Appendix 2.
Appendix 2.
Appendix 2.
Appendix 2.

Appendix 2. Significant Drug-Drug Interactions Involving Antipsychotics

Enlarge table

Appendix 3. Significant Drug-Drug Interactions Involving Mood Stabilizers

Appendix 3. Significant Drug-Drug Interactions Involving Mood Stabilizers

Appendix 3.
Appendix 3.
Appendix 3.
Appendix 3.

Appendix 3. Significant Drug-Drug Interactions Involving Mood Stabilizers

Enlarge table

Appendix 4. Significant Drug-Drug Interactions Involving Other Psychotropic Agents and Nonpsychotropic Agents

Appendix 4. Significant Drug-Drug Interactions Involving Other Psychotropic Agents and Nonpsychotropic Agents

Appendix 4.
Appendix 4.
Appendix 4.

Appendix 4. Significant Drug-Drug Interactions Involving Other Psychotropic Agents and Nonpsychotropic Agents

Enlarge table